Schillaci: La resistenza è un’emergenza globale. No al fai da te’
Risultati per: Uso di Benzodiazepine e rischio negli anziani
Questo è quello che abbiamo trovato per te
In Italia 2 milioni di giovani non protetti dal virus hpv, a rischio per vari tumori
Oncologi, ‘subito un piano di recupero per la prevenzione’
Sciopero medici, domani 1,2 milioni prestazioni a rischio
I sindacati contestano mancate assunzioni.’Abuso di precettazioni’
++ Sciopero medici, domani 1,2 milioni prestazioni a rischio ++
Sindacati: ‘Anche 15mila interventi. Garantita l’urgenza’
Marsh Italia, gestione del rischio per una sanità più sicura
Araldi, ‘con MedMal Report identifichiamo aree più a rischio’
Indagine sull’appropriatezza d’uso proflattico degli antibiotici in odontoiatria
Ospedalizzazioni da RSV (virus respiratorio sinciziale) negli anziani nella provincia di Bari: analisi di un proxy utile per una strategia vaccinale
Vaccinazione anti-Covid e rischio di malattia grave
Riacutizzazione di BPCO (R-BPCO) e uso di Gabapentinoidi
Antibiotici a neonati, al via studio per prevenire uso improprio
UniCamillus, oggi 99,6% dei piccoli trattato nel modo sbagliato
Diabete tipo 1, screening bimbi riduce 94% rischio complicanze
Cherubini (Siedp) “evitabili in oltre 450 bimbi ogni anno”
Abstract 4140180: The Effect of Benzodiazepine Use in Patients with Atrial Fibrillation and Obstructive Sleep Apnea
Circulation, Volume 150, Issue Suppl_1, Page A4140180-A4140180, November 12, 2024. Introduction:Sleep apnea is a common sleep disorder that can worsen atrial fibrillation(AF) prognosis. Benzodiazepines(BZD) are commonly prescribed for insomnia, which often accompanies sleep apnea. However, BZDs have been associated with worsening of sleep apnea due to respiratory depression, pharyngeal muscle relaxation, and increase of arousal threshold, which all may lead to prolonged hypoxia. There is little research on the effect of BZD use in AF patients with sleep apnea. Therefore, the objective of this study is to investigate the effects of BZD usage on outcomes in the AF population with sleep apnea.Methods:Data from patients with AF and sleep apnea seen at Tulane Medical Center between 2010 and 2019 was obtained from Research Action for Health Network(REACHnet), a Clinical Research Network in PCORnet®. Patients with AF and sleep apnea were divided between those with a prescription of BZD and those without BZD. These two groups were compared using the Kaplan-Meier method for time-to outcome for all-cause mortality, ischemic stroke, myocardial infarction(MI), and hospitalizations in the five years following their AF diagnosis. Cox regression analysis was used to investigate proportional hazards and control for demographics, comorbidities, and medication use.Results:There were 524 total patients included with AF and sleep apnea. Of these, 413(78.8%) were not prescribed BZDs, while 111(21.1%) were taking BZDs. Use of BZDs was associated with worse outcomes. In the no BZD and the BZD group over the 5 years following AF diagnosis, the rate of mortality was 6.1% and 12.6%(p
Disturbi psichici in crescita in Trentino, giovani più a rischio
In nove anni utenti raddoppiati, in lieve calo i suicidi
Aviaria, in Francia il rischio si alza da 'moderato' a 'alto'
‘Persistente infezione nei corridoi migratori’
La sonnolenza diurna legata a un triplo rischio di 'pre-demenza'
Disturbo da lentezza motoria e deficit di memoria
Protocollo Fiaso-Egualia per l'uso corretto dei farmaci
Obiettivo ridurre la spesa privata a carico dei cittadini